Aim immunotech announces publication of data from roswell park comprehensive cancer center phase 1 study evaluating ampligen® as a component of a chemokine-modulating (ckm) regimen in metastatic triple-negative breast cancer

Ocala, fla., nov. 14, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) today announced the publication of results from the phase 1 study at roswell park comprehensive cancer center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including aim immunotech inc.'s drug candidate ampligen® (also known as rintatolimod), interferon Α-2b and celecoxib, followed by pembrolizumab.
AIM Ratings Summary
AIM Quant Ranking